Abstract

A REVIEW ON PATENTED NANOTECHNOLOGY USED FOR OCULAR DRUG DELIVERY

Mamta Yadav* and Meenakshi Chauhan

Abstract

Blindness is a significant health concern worldwide that has a substantial impact on afflicted individuals and their families, and is associated with enormous socio-economical consequences. Numerous scientific efforts have been made till date to provide an efficient ocular drug delivery system, but still, it is challenging for pharmaceutical scientists. A suitable drug/gene delivery system that can sustain and deliver therapeutics to the target tissues and cells is a key requirement for ocular therapies. Most of the ocular diseases are treated by topical drug application in the form of suspensions, solutions and ointments. But because of various anatomical and pathophysiological barriers prevailing in the eye, these conventional dosage forms suffer from the problem of poor ocular bioavailability. The application of nanotechnology in medicine is experiencing rapid progress, and the recent developments in nanomedicine-based therapeutic approaches may bring essential benefits to address the leading causes of blindness associated with cataract, glaucoma, diabetic retinopathy and retinal degeneration. This review provides an insight of various limitations associated with ocular drug delivery, summarizes recent findings and patents on various nanotechnology products in ocular drug delivery.

Keywords: Ocular, Drug delivery, Patents, Dendrimers, Nanoparticles, Ocular Gene Therapy.